US3659104A - Method of measuring serum thyroxine - Google Patents

Method of measuring serum thyroxine Download PDF

Info

Publication number
US3659104A
US3659104A US3659104DA US3659104A US 3659104 A US3659104 A US 3659104A US 3659104D A US3659104D A US 3659104DA US 3659104 A US3659104 A US 3659104A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
column
serum
gel
thyroxine
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Jack Gross
Amirav Gordon
Lloyd Alan Schick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JERUSALEM THE, University of
Original Assignee
JERUSALEM THE, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/825Pretreatment for removal of interfering factors from sample
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/826Additives, e.g. buffers, diluents, preservatives

Abstract

A new and improved in vitro concept in measuring serum thyroxine (T-4) is disclosed which employs an alkaline crosslinked dextran gel (Sephadex) column to dissociate and separate the T-4 from the serum protein in a single operation. An isotope dilution technique combined with saturation analysis is used to estimate the T-4 content in serum.

Description

United States Patent Gross et al.

[ 51 Apr. 25, 1972 [54] METHOD OF MEASURING SERUM THYROXINE Jack Gross; Amlrav Gordon, both of Jcr-usalcm. Israel; Lloyd Alan Schlck, Elkhart, lnd.

inventors:

Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Filed: June 29, 1970 Appl. No.: 51,005

US. Cl. ..250/83 SA, 23/230 B, 250/106 T Int. Cl. ..G21h 5/02 Field of Search ..250/83 R, 83 SA, 106 T;

[56] References Cited UNITED STATES PATENTS 3.451.777 6/1969 Di Guilio ..2Sl)/H3 SA X 3,507,618 4/1970 Murty et al ..23/230 8 Primary Examiner-James W. Lawrence Assistant Examiner-Davis L. Willis Attorney-Joseph C. Schwalbach, Michael A. Kondzella, Louis E. Davidson and Harry T. Stephenson [5 7] ABSTRACT 7 Claims, No Drawings METHOD OF MEASURING SERUM THYROXINE BACKGROUND OF THE INVENTION The thyroid gland is extremely important in the animal body because of its effect upon the basal metabolic rate. This effect is regulated by the thyroxine hormone which is released in response to nervous or hormonal stimuli.- Thyroxine enters the circulatory system and acts either directly upon the cell or indirectly upon other hormonal systems. Abnormal activity of the thyroid is a common malady in humans. In hypothyroidism, the body has decreased thyroid activity which is manifest by such diseases as cretinism and myxedema. Hyperthyroidism is a state of excessive thyroid activity in which one becomes nervous, develops an increased pulse rate and sometimes goiter.

Thyroid deficiency was associated with a reduced metabolic rate as early as 1895 and several systems based on basal metabolic rate were devised for estimating thyroid activity. However, such systems were not reliable, so more direct and precise methods were sought. In 1896, iodine was discovered in thyroid extract but the relationship between blood iodine level and thyroid function was not firmly established until I933. This led to the use of protein-bound iodine as a means of estimating thyroid function, and by 1955 the FBI test was standard for checking thyroid activity. It soon became apparent that this test was influenced by the administration of other iodine containing compounds to the patient. Thus, the butanol-extractable iodine (BEI) procedure was devised which gave better correlation between serum iodine levels and the clinical findings but was likewise non-specific for T-4.

A major advance in T-4 analysis occurred in 1959 when Galton et al., Biochem. J. 72, 310 (1959) liberated T-4 from serum protein by hydrolysis and separated it from other iodine compounds by passage through a resin column. Later, Pileggi et al., J. Clin. Endocr. Met. 21, 1272 (1961) developed this column chromatographic procedure into a clinically usable method.

In l964, Murphy et al., J. Clin. Endocr. Met. 24, 187 (1964) developed a T-4 assay based upon competitive protein binding and isotopic dilution which required the initial extraction of T-4 from the serum with alcohol followed by centrifugation and drying. Although this test was highly specific, only 80 percent of the T-4 could be recovered from the serum.

More recently, U.S. Pat. No. 3,471,553 set forth still another column chromatography T-4 assay in which an anionexchange resin is adjusted to an alkaline pH of about 12 to dissociate the thyroxine from its albumin and globulin carriers. The diluted serum solution is then poured onto the resin wherein proteins, amino acids, thyroxine, iodotyrosine and inorganic iodine are adsorbed. Successive washes with acetate buffer isopropyl alcohol and acetic acid remove serum proteins, iodothyronines and some organic iodine compounds. Further treatment of the resin with 50 percent acetic acid at a pH of 2 quantitatively removes T-4. Even though many modifications have been made in the original T-4 by column assay of Galton et al., the procedure is substantially the same i.e., a diluted serum sample is applied to an ion exchange resin. The unwanted contaminants are then eluted from the column and discarded. Following this, the hormones to be measured are eluted, collected and the T-4 determined by iodine analysis.

SUMMARY OF THE INVENTION The present invention for determining T4 is based on the competitive protein binding principle which is a modified form of saturation analysis. The T-4 to be determined is mixed with a detenninate sample of T-4 labeled with a trace amount of radioactive isotope. A binding agent is added which will bind a definite number of molecules. Since the binding agent cannot distinguish between the labeled and unlabeled molecules, they compete with each other on an equal basis for the binding sites. These molecules are uniformly mixed so that the binding agent will bind them in the same ratio as that existing in the free or unbound state. As the concentration of the unlabeled molecules increases, the ratio becomes smaller and fewer labeled molecules are bound by the binding agent, leaving more of the labeled molecules in the free state. By calibrating the binding of labeled molecules in the presence of a known amount of unlabeled molecules, a quantitative procedure can be established.

In practicing the present invention, the crosslinked dextran gel column acts as the secondary binding agent for the unbound or free T-4, whereas the primary binding agent is a thyroxine (T-4) binding protein. First, a measured amount of serum is mixed with some T-4 labeled with radioactive iodine on top of the column. Both the column and T4 mixture are at pHl2 to 13. At this pH, the T-4 binding serum proteins such as prealbumin, albumin and thyroxine binding globulin are completely dissociated from T4. As the mixture flows down the column, the T-4 is bound by the dextran gel. The serum proteins are washed away with a barbital buficr at a pH of 8.6 which automatically adjusts the pH of the column to that of the buffer. The pH is such that the transfer of the T-4 from the column to the primary binding agent is facilitated. The primary binding agent dissolved in barbital buffer is then added. Equilibrium is quickly established between the two binding agents and the primary binder is washed away carrying a portion of the T-4 with it. By measuring the amount of radioactivity on the column before and after treatment with the primary binding agent and comparing the percent retained by the column with a standard curve in which percent retained is plotted against T-4 concentration, the amount ofT-4 in the serum can be determined.

DESCRIPTION OF THE PREFERRED EMBODIMENTS This invention is predicated upon the discovery that a dextran gel column retains radioactive T-4 very well up to a pH of 9. Between pH 9 and ll, radioactive P4 is rapidly eluted from the column whereas above pH 1 l the retention of T-4 by the column is greatly enhanced. Thus, dextran gel binds T-4 but not protein, whereas anion exchange resins bind both T4 and protein which are removed nonspecifically and only under acidic conditions.

The dextran gels employed in the column are crosslinked with various amounts of epichlorohydrin as described in U.S. Pat. No. 3,042,667 and have a water regain of from I to 5 grams per gram of dry gel product. Such gels are produced commercially by Pharmacia of Uppsala, Sweden and sold under the trade name of Sephadex in various molecular weight ranges and sieve sizes. Thus, Sephadex G-lO has a water regain of one gram per gram of dry gel, Sephadex G-l5 has a water regain of 1.5 grams per gram of dry gel, Sephadex 6-25 has a water regain of 2.5 grams per gram of dry gel and Sephadex G50 has a water regain of 5 grams per gram of dry gel. Of these gels, Sephadex G-25 is preferred.

The dextran gel column employed in this invention is prepared by suspending 500 grams of dry gel in two liters of distilled water and allowing it to hydrate overnight. Fines are removed by slurrying the gel in 0.1 N sodium hydroxide for about 5 minutes, allowing it to settle for 15 minutes and then drawing off the supernatant by suction. The process is repeated three times and the gel is suspended in 4,400 milliliters of 0.1 N sodium hydroxide. Four milliliters of this suspension is placed in a six milliliter plastic syringe barrel having a diameter of 13 millimeters and a length of 66 millimeters. Each barrel is prefitted with a bottom closure means, for example, a removable cap, and a detergent treated sintered polyethylene retaining disc about l.5 millimeters thick and having a diameter of 13 millimeters is pressed coaxially to the bottom of the plastic barrel. After placement of the suspension in the syringe barrel, the suspension is stirred and permitted to settle free of air bubbles after which another detergent-treated sintered polyethylene disc, like the first-mentioned disc, is inserted into the syringe barrel and pushed coaxially into firm contact with the gel. About 1.5 milliliters of sodium hydroxide solution remains above the upper disc. The upper end of the syringe is closed with a new polyethylene cap. This procedure provides a column containing about 450 milligrams of gel.

The T-4 test herein contemplated is performed by utilizing the gel column thus prepared as follows:

1. Remove the top cap from the column, decant the supernatant and place the column in an upright position.

2. Add 0.45 milliliter of a 0.1 N sodium hydroxide solution containing about 0.10 microcuries of radioactive T-4 to provide from 60,000 to 120,000 counts per minute of gamma radioactivity.

3. Add 0.1 milliliter of serum sample and mix with the radioactive T-4. If a standard is to be determined, nonradioactive T4 is added.

4. Remove the bottom cap and allow the serum mixed with the radioactive T4 to flow into the column.

5. Wash the column with 4 milliliters of a 0.075 molar aqueous barbital solution buffered to a pH of 8.6.

6. Replace the bottom cap and determine the radioactivity of the column in counts per minute with a gamma counter.

7. Remove the bottom cap and add one milliliter of 0.15% human a-globulin dissolved in 0.075 molar barbital buffer.

8. Add 4 milliliters of 0.075 molar barbital buffer at pH 8.6 and allow to flow through the column.

9. Replace the bottom cap and again determine the radioactivity of the column.

10. Calculate the percentage of radioactivity retained on the column and determine the T-4 content of the serum sample by comparing the percent retention to a standard curve prepared with T-4 solutions of known concentrations.

Although a specific embodiment of the test method comprising this invention has been described, it should be understood that several variations are possible. Thus, the gel column can be made alkaline by potassium hydroxide or ammonium hydroxide if desired. Human a-globulin can be replaced with an equivalent amount of human serum, bovine serum or bovine gamma globulin as the primary binding agent. Aqueous alkaline solutions buffered to a pH of from 8 to 10 with sodium phosphate or tris (hydroxymethyl) amino methane can be used at concentrations from 0.01. to 0.2 molar, but an aqueous barbital solution is preferred, since it facilitates better quantitation when used to dissolve the human a-globulin or other binding agents.

Another variation of the present invention involves determining the radioactivity of the solutions before addition to the gel column and after elution therefrom rather than determining the radioactivity of the column itself. Percent retention is then determined by a difference calculation. However, for the sake of efficiency, it is preferable to determine the radioactivity of the column before and after elution.

Assays for T-4 by the column methods of the prior art should not be confused with the present method which involves saturation analysis using a radioactive tracer. Previously, a column was utilized only to separate contaminating iodines prior to analysis of iodine. In certain cases, this was done by using an ion exchange resin column at an alkaline pH, and iodine analysis was performed on the T-4 recovered from the column by measuring the effect of iodine on the ceric-arsenious acid reaction. The saturation analysis method herein disclosed is a direct determination of thyroxine, rather than the indirect measurement of thyroxine as iodine.

What is claimed is:

1. A process for the in vitro determination of thyroxine in serum comprising:

A. adding a predetermined quantity of serum to be tested and a predeterminate radioactive thyroxine solution to a column packed with a dextran gel crosslinked with epichlorohydrin and having a water regain of from 1 to 5 grams per gram of dry gel at a pH of at least about 1 l and allowing the serum and thyroxine to flow into the column;

B. washing the column with an aqueous alkaline solution; C. adding a predetermined quantity of an eluting agent containing thyroxine binding protein to partially remove the thyroxine on the column;

D. determining the ratio of radioactive thyroxine retained by the column to that originally added, and

E. calculating the thyroxine content of the serum by comparing the percent retention to that obtained with known concentrations of thyroxine in serum.

2. A process as in claim 1 wherein the radioactivity of the gel column is determined before and after elution to determine the ratio of radioactive thyroxine retained by the column to that originally added.

3. A process as in claim 1 wherein the aqueous alkaline solution is buffered to a pH of about 8 to 10.

4. A process as in claim 3 wherein the aqueous alkaline solution is a barbital buffer having a pH of 8.6.

5. A process as in claim 1 wherein the pH of the column is maintained at about 11 to 13.

6. A process as in claim 1 wherein the eluting agent is serum.

7. A process as in claim 1 wherein the eluting agent is human a-globulin.

"1 TED STATES ATENT @FFEEE QHEQA @F QEH Patent No. 3,659,104 Dated April 25 1972 Inventor(s) Jack Gross Amirav Gordon and Lloyd Alan S chick It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 4 Line 20 Third word should read "determinate" rather than "predeterminate" Signed and sealed this 2)th day of August 1972.

(SEAL) Attest:

EDWARD -I.FL..dZTCHEP-.,JR. ROBERT GOTTSCHALK Attesting Officer Commissioner of Patents T5333? UNITED STATES PATENT 0mm I CERT'IFIGA'EE Dated April 2L5. 1972 Patent No. 3,659 lO4 Inventor(s) Jack Gross Amirav Gordon and Lloyd Al an It is certified that error appear s in t he ab otl edderxtified. I I

and that said Letters Patent are hereby cbrrected as shown beldw z Third word should read Column 4 Line 20 v determinaterather than "predeterminate" Signed and sealed this ZQtlmday of Aggust 1972. r

(SEAL) Attestl EDWARD'iVi'.FLE1TGHEH,JR. ROBERT GOTTSCHALKN Attesting Officer Commissioner of, Patents

Claims (6)

  1. 2. A process as in claim 1 wherein the radioactivity of the gel column is determined before and after elution to determine the ratio of radioactive thyroxine retained by the column to that originally added.
  2. 3. A process as in claim 1 wherein the aqueous alkaline solution is buffered to a pH of about 8 to 10.
  3. 4. A process as in claim 3 wherein the aqueous alkaline solution is a barbital buffer having a pH of 8.6.
  4. 5. A process as in claim 1 wherein the pH of the column is maintained at about 11 to 13.
  5. 6. A process as in claim 1 wherein the eluting agent is serum.
  6. 7. A process as in claim 1 wherein the eluting agent is human Alpha -globulin.
US3659104A 1970-06-29 1970-06-29 Method of measuring serum thyroxine Expired - Lifetime US3659104A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5100570 true 1970-06-29 1970-06-29

Publications (1)

Publication Number Publication Date
US3659104A true US3659104A (en) 1972-04-25

Family

ID=21968790

Family Applications (1)

Application Number Title Priority Date Filing Date
US3659104A Expired - Lifetime US3659104A (en) 1970-06-29 1970-06-29 Method of measuring serum thyroxine

Country Status (7)

Country Link
US (1) US3659104A (en)
JP (1) JPS5331399B1 (en)
CA (1) CA955159A (en)
DE (1) DE2132112C3 (en)
ES (1) ES392664A1 (en)
FR (1) FR2100008A5 (en)
GB (1) GB1351836A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753655A (en) * 1971-11-09 1973-08-21 B Schreiber Process for isolation and separation of thyroid hormones
US3816076A (en) * 1971-06-15 1974-06-11 Merck Patent Gmbh Process for the determination of thyroxine
US3911096A (en) * 1972-06-23 1975-10-07 Professional Staff Ass Of The Radioimmunoassay for measurement of thyroxine (T{HD 4{B ) and triiodothyonine (T{HD 3{B ) in blood serum
US3918909A (en) * 1971-09-21 1975-11-11 Philips Corp Apparatus for performing saturation analyses
US3929410A (en) * 1970-11-09 1975-12-30 Benjamin Schloss Analytical process
US3941564A (en) * 1973-09-13 1976-03-02 Miles Laboratories, Inc. Method for assessing thyroid function
US3947564A (en) * 1973-05-29 1976-03-30 Bio-Rad Laboratories Radioactive determination of serum thyroxine
US3961894A (en) * 1973-04-24 1976-06-08 Yissum Research Development Company Test for determination of triiodothyronine
DE2806860A1 (en) * 1977-03-10 1978-09-14 Lepetit Spa A method for determining the free fraction of a hormone in a biological fluid of concentration
US4170454A (en) * 1978-03-30 1979-10-09 Union Carbide Corporation Process for the preparation of a solid-phase radioimmunoassay support and use thereof
US4225576A (en) * 1978-11-20 1980-09-30 Miles Laboratories, Inc. Combined radioimmunoassay for triiodothyronine and thyroxine
US4230797A (en) * 1975-04-28 1980-10-28 Miles Laboratories, Inc. Heterogenous specific binding assay employing a coenzyme as label
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
USRE32098E (en) * 1972-06-23 1986-03-25 Research And Education Institute, Inc. Radioimmunoassay for measurement of thyroxine (T4) and triiodothyronine (T3) in blood serum
US5217903A (en) * 1990-05-15 1993-06-08 Trustees Of Boston University Measuring connective tissue breakdown products in body fluids

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301139A (en) * 1979-06-21 1981-11-17 Ames-Yissum Ltd. Multilayer column chromatography specific binding assay method, test device and test kit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451777A (en) * 1965-08-20 1969-06-24 Walter Di Giulio Method and apparatus for determining the thyroid hormone content of blood
US3507618A (en) * 1964-11-27 1970-04-21 Squibb & Sons Inc Apparatus and method for determining thyroid function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507618A (en) * 1964-11-27 1970-04-21 Squibb & Sons Inc Apparatus and method for determining thyroid function
US3451777A (en) * 1965-08-20 1969-06-24 Walter Di Giulio Method and apparatus for determining the thyroid hormone content of blood

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929410A (en) * 1970-11-09 1975-12-30 Benjamin Schloss Analytical process
US3816076A (en) * 1971-06-15 1974-06-11 Merck Patent Gmbh Process for the determination of thyroxine
US3918909A (en) * 1971-09-21 1975-11-11 Philips Corp Apparatus for performing saturation analyses
US3753655A (en) * 1971-11-09 1973-08-21 B Schreiber Process for isolation and separation of thyroid hormones
US3911096A (en) * 1972-06-23 1975-10-07 Professional Staff Ass Of The Radioimmunoassay for measurement of thyroxine (T{HD 4{B ) and triiodothyonine (T{HD 3{B ) in blood serum
USRE32098E (en) * 1972-06-23 1986-03-25 Research And Education Institute, Inc. Radioimmunoassay for measurement of thyroxine (T4) and triiodothyronine (T3) in blood serum
US3961894A (en) * 1973-04-24 1976-06-08 Yissum Research Development Company Test for determination of triiodothyronine
US3947564A (en) * 1973-05-29 1976-03-30 Bio-Rad Laboratories Radioactive determination of serum thyroxine
US3941564A (en) * 1973-09-13 1976-03-02 Miles Laboratories, Inc. Method for assessing thyroid function
US4230797A (en) * 1975-04-28 1980-10-28 Miles Laboratories, Inc. Heterogenous specific binding assay employing a coenzyme as label
DE2806860A1 (en) * 1977-03-10 1978-09-14 Lepetit Spa A method for determining the free fraction of a hormone in a biological fluid of concentration
US4170454A (en) * 1978-03-30 1979-10-09 Union Carbide Corporation Process for the preparation of a solid-phase radioimmunoassay support and use thereof
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
US4225576A (en) * 1978-11-20 1980-09-30 Miles Laboratories, Inc. Combined radioimmunoassay for triiodothyronine and thyroxine
US5217903A (en) * 1990-05-15 1993-06-08 Trustees Of Boston University Measuring connective tissue breakdown products in body fluids

Also Published As

Publication number Publication date Type
FR2100008A5 (en) 1972-03-17 application
JPS5331399B1 (en) 1978-09-02 grant
GB1351836A (en) 1974-05-01 application
DE2132112B2 (en) 1974-02-21 application
DE2132112C3 (en) 1974-09-19 grant
CA955159A (en) 1974-09-24 grant
CA955159A1 (en) grant
ES392664A1 (en) 1973-08-01 application
DE2132112A1 (en) 1972-01-27 application

Similar Documents

Publication Publication Date Title
Murphy The determination of thyroxine by competitive protein-binding analysis employing an anion-exchange resin and radiothyroxine
Morgan et al. Studies of an inhibitor of the two antibody immunoassay system
PILEGGI et al. DETERMINATION OF IODINE COMPOUNDS IN SERUM. I. SERUM HYROXINE IN THE PRESENCE OF SOME IODINE CONTAMINANTS
Tamura et al. Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum
Bussolati et al. Immunofluorescent localization of calcitonin in the'C'cells of pig and dog thyroid
STERLING et al. Resin uptake of I131-triiodothyronine as a test of thyroid function
US3555143A (en) Method for the determination of proteins and polypeptides
Hughes-Jones et al. Optimal conditions for detecting blood group antibodies by the antiglobulin test
Bennhold et al. Comparative studies on the half-life of I 131-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia
Waalkes The determination of serotonin (5-hydroxytryptamine) in human blood
Pensky et al. Studies on thyroxine-binding globulin (TBG): II. Separation from human serum by affinity chromatagraphy
Kaplan et al. Radioimmunoassay of Platelet Factor 4 and β‐Thromboglobulin: Development and Application to Studies of Platelet Release in Relation to Fibrinopeptide A Generation
Herbert et al. Coated charcoal immunoassay of insulin
US4138474A (en) Method and device for immunoassay
US4196185A (en) Immunoassay for phencyclidine
Chiauzzi et al. Inhibition of Follicle-Stimulating Hormone Receptor Binding by CirculatingImmunoglobulins
McDuffie et al. A comparative study of methods used for analysis of specific precipitates in quantitative immunochemistry
Addison et al. Immunoradiometric assay of parathyroid hormone
Nisonoff et al. Heterogeneity and average combining constants of antibodies from individual rabbits
DEGROOT et al. Triiodothyronine binding to isolated liver cell nuclei
Borisy A rapid method for quantitative determination of microtubule protein using DEAE-cellulose filters
US4039652A (en) Column method of immunoassay employing an immobilized binding partner
Schuhmacher et al. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl
Aherne Immunoassays in the analysis of water
Surks et al. A new radioimmunoassay for plasma L-triiodothyronine: measurements in thyroid disease and in patients maintained on hormonal replacement